[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"KU Leuven\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":698},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,44,74,104,133,162,196,222,248,272,298,327,350,370,394,422,451,476,506,534,562,588,613,644,664],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100643361","disease-extent-in-stage-iv-lobular-carcinoma-the-aid-of-imaging-and-liquid-biopsy-analyses-100643361",false,"NCT07635654","Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses","DELILA","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. ECOG from 0 to 2\n4. Patient with stage IV ILC, either de novo or after prior (curative) treatment for early ILC. Histological subtype confirmed on primary tumor or on metastatic tissue. Patients that are diagnosed with stage IV breast cancer that have a mixed ILC\u002FIBC-NST histology of the primary tumor (mixed histology within the same primary lesion) will also be able to participate and will be analyzed in an exploratory cohort.\n5. Confirmation of hormone receptor positive (HR+)\u002FHER2- disease either on new biopsy or archival tissue (e.g. primary tumor)\n6. Multifocal or bilateral disease is allowed if all evaluated foci present with HR+\u002FHER2- ILC\n7. Starting first line of treatment for metastatic ILC\n\nExclusion Criteria:\n\n1. Presence of a contraindication to perform WB-DWI\u002FMRI\n2. Presence of severe claustrophobia\n3. Presence of a contraindication to use IV contrast for CT or PET\u002FCT (e.g. allergy, severe renal failure) in case a non-contrast PET\u002FCT cannot be performed\n4. Patients considered to have oligometastatic disease who are expected to undergo locoregional treatment\n5. Presence of other malignancies in recent medical history (\\\u003C5 years)\n6. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive\n7. Adults who are the subject of a legal protection measure or who are unable to express their consent.","ALL","18 Years",{"count":5,"type":20},"ESTIMATED","INTERVENTIONAL",[23],"NA","Metastatic invasive lobular carcinoma (ILC) is a distinct breast cancer subtype characterized by loss of E-cadherin and a diffuse growth pattern that makes metastases difficult to detect with standard imaging such as computed tomography (CT) or 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)\u002FCT. As a result, disease burden in patients with ILC is frequently underestimated, progression is identified later than clinically optimal, and many patients are excluded from clinical trials due to insufficiently measurable disease.\n\nWhole-body diffusion-weighted magnetic resonance imaging (WB-DWI\u002FMRI) is a radiation-free imaging technique that has demonstrated improved sensitivity for detecting metastases-including peritoneal, bone, and nodal disease-in ILC. Retrospective studies suggest that WB-DWI\u002FMRI can identify clinically relevant progression not visible on standard imaging. However, prospective evidence in ILC is lacking. Circulating tumor DNA (ctDNA) has also shown promise as a minimally invasive biomarker for monitoring treatment response, with early molecular changes often preceding radiologic progression, but data specific to ILC remain limited.\n\nThe DELILA study is a prospective, multicenter clinical trial conducted at University Hospitals Leuven and Institut Jules Bordet. The study aims to enroll 43 patients starting first-line systemic therapy for metastatic hormone receptor positive human epidermal growth factor receptor 2 negative (HR+\u002FHER2-) ILC. Participants undergo serial dual imaging-WB-DWI\u002FMRI and standard-of-care imaging-at baseline, at 1 month, and approximately every 3 months for up to 30 months or until disease progression. At each imaging time point, blood samples are collected for ctDNA analysis and Ca15.3 tumor marker assessment. Patient-reported psychological burden related to repeated imaging and blood sampling is evaluated using validated questionnaires.\n\nThe primary objective is to assess the added value of WB-DWI\u002FMRI in detecting disease progression that informs clinical decision-making compared to standard imaging. Secondary objectives include evaluating whether ctDNA or Ca15.3 dynamics reflect disease evolution, assessing measurability of lesions with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and MRI-specific criteria, identifying early biomarkers of treatment response using Apparent Diffusion Coefficient (ADC) changes and ctDNA kinetics, and characterizing the psychological impact of trial procedures.\n\nThis study will provide the first adequately powered prospective evidence on the clinical utility of WB-DWI\u002FMRI and liquid biopsy monitoring in metastatic ILC. Results may support implementation of WB-DWI\u002FMRI as a routine imaging strategy, guide imaging frequency through biomarker-informed approaches, and improve patient experience and trial eligibility for individuals living with metastatic ILC.",[26],"Invasive Lobular Breast Carcinoma",[28,29,30,31],"Invasive lobular carcinoma","Imaging","WB-DWI MRI","Liquid biopsy","NOT_YET_RECRUITING","2026-06-03",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":20},"2026-07-01",{"date":40,"type":20},"2030-06-30",{"name":42,"class":43},"KU Leuven","OTHER",{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100637358","effect-of-foot-position-during-rehabilitation-of-achilles-tendinopathy-on-tendon-mechanics-and-symptoms-100637358","NCT07623408","Effect of Foot Position During Rehabilitation of Achilles Tendinopathy on Tendon Mechanics and Symptoms.","The Effect of Foot Positioning During a 12-week Supervised Training Program on Achilles Tendon Mechanics and Function in Individuals With Mid-portion Achilles Tendinopathy.","The following inclusion criteria will be used:\n\nPATIENTS WITH ACHILLES TENDINOPATHY:\n\n* Voluntary written Informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* Age between 18 and 65 years old\n* BMI between 18.5-30\n* Showing history of intermittent episodes of Achilles tendon pain lasting more than 3 consecutive weeks within the past 6 months.\n* Presenting palpable focal thickening of the Achilles tendon.\n* Having pain originating from the Achilles tendon on palpation of thickened tendon and on loading activities (such as running, jumping).\n* Showing sonographic evidence of tendinopathy, i.e. focal thickening and hypoechocity, consistent with previously reported sonographic characteristics diagnosed of tendinopathy.\n\nPrior to start of the data collection, these inclusion criteria (specifically the ones concerning Achilles Tendinopathy presence) will be checked by a medical doctor at SMAC (Sports medical advisory centre Leuven). Only if they confirm the diagnosis, patients are included in the study.","65 Years",{"count":53,"type":20},60,[23],"This study will investigate whether a 12-week load-based exercise program performed with an externally rotated foot position (\"toes-out\") leads to different changes in intra-tendinous sliding, symptoms, and function compared to a standard exercise program performed with a neutral foot position in individuals with mid-portion Achilles tendinopathy. In addition, physical activity will be monitored during and after the intervention to examine how daily loading patterns relate to symptoms and functional recovery over a 6-month period.",[57],"Achilles Tendinopathy (AT)",[59,60,61,62,63,64],"Achilles Tendinopathy","Exercise therapy program","Achilles Tendon","Rehabilitation","Foot position","homogeneous motions","RECRUITING","2026-05-28",{"date":33,"type":36},{"date":69,"type":36},"2026-02-19",{"date":71,"type":20},"2027-08-31",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100609326","effect-of-imt-in-patients-after-acute-exacerbations-of-copd-100609326","NCT07213128","Effect of IMT in Patients After Acute Exacerbations of COPD","The Effect of Home-based Inspiratory Muscle Training Compared to Usual Care on Readmission Rate in Patients After a Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Randomised, Multicentre, Parallel Group Clinical Trial: IN-SPIRED Trial","IN-SPIRED","Inclusion Criteria:\n\n* Patients admitted to the hospital ≥3 days for AECOPD\n* Read and speak French, Dutch or English\n* Age ≥ 35 years\n* Able to provide informed consent\n* Possessing a smartphone, compatible with the tele-monitoring app and able to perform video meetings.\n\nExclusion Criteria:\n\n* Patients already performing IMT at time of inclusion\n* Patients with estimated \\\u003C90 days life expectancy\n* Non-COPD pulmonary disease as primary diagnosis\n* Active malignancy\n* Inability to perform IMT or response to questionnaires (e.g., neurological\u002Fcognitive impairment)\n* Acute instable cardiac arrythmia or ischemia\n* Acute pneumothorax\n* Planned lung volume reduction procedure \\\u003C180days\n* Waitlisted for lung transplantation\n* Patients admitted to an in-hospital rehabilitation ward\n* Patients included in other interventional trial related to COPD that would interfere with our trial outcomes.","35 Years",{"count":84,"type":20},358,[23],"The goal of this clinical trial is to test whether home-based inspiratory muscle training can reduce hospital readmissions and death in patients recovering from a severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD).\n\nThe main questions this study aims to answer are:\n\nDoes adding home-based inspiratory muscle training to usual care lower the risk of all-cause hospital readmission or death within 180 days after discharge? Does inspiratory muscle training improve respiratory muscle strength, symptoms of dyspnea, quality of life, and functional capacity compared to usual care?\n\nResearchers will compare patients randomized to:\n\nIntervention group: Home-based inspiratory muscle training plus usual care Control group: Usual care only\n\nto see if inspiratory muscle training leads to fewer readmissions and deaths, and better patient-reported and physiological outcomes.\n\nParticipants will:\n\nBe hospitalized for ≥3 days due to AECOPD, age ≥35 years, able to consent, and own a compatible smartphone.\n\nIn the intervention group, receives usual care and additionally inspiratory muscle training:\n\nInspiratory muscle training twice daily for 90 days, then once daily up to day 180, with remote telemonitoring via a smartphone app and online supervised sessions.\n\nThe control group will continue with usual care (pharmacological treatment, smoking cessation advice, vaccinations, and referral to pulmonary rehabilitation if available).\n\nFollow-up assessments will include hospital readmissions, survival, and quality of life questionnaires up to 12 months after discharge.",[88,89,90],"Chronic Obstructive Pulmonary Diseases","COPD","Symptom Exacerbation",[92,93,94,95],"Inspiratory muscle training","Respiratory muscle training","acute exacerbation","chronic obstructive pulmonary disease","2026-05-27",{"date":66,"type":36},{"date":99,"type":36},"2026-01-06",{"date":101,"type":20},"2029-02",{"name":42,"class":43},12,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":73},"100615668","postprandial-effect-of-isocaloric-challenge-meals-enriched-with-indigenous-fruits-and-vegetables-on-glucose-metabolism-in-individuals-with-type-2-diabetes-in-wakiso-district-uganda-100615668","NCT07295600","Postprandial Effect of Isocaloric Challenge Meals Enriched With Indigenous Fruits and Vegetables on Glucose Metabolism in Individuals With Type 2 Diabetes in Wakiso District, Uganda","Inclusion Criteria:\n\n* Fasting blood sugar \\>= \\[7 mmol\u002FL\\](based on medical records)\n* Diabetic regimen for at least 6 months\n* Type 2 diabetes\n* Plans to continue staying in the same location for the next 6 months\n\nExclusion Criteria:\n\n* Taking dietary supplements\n* Type 1 diabetes\n* Tuberculosis co-infection\n* Renal failure\n* Liver cirrhosis\n* Chronic pancreatitis\n* Pregnancy and Lactation\n* Regular sports activity\n* Parallel participation in another clinical trial\n* On treatment for dyslipidaemia,\n* On treatment for hypertension\n* Very low blood pressure (\\\u003C 90\u002F50 mmHg)\n* Allergic reactions to test products","30 Years","60 Years",{"count":113,"type":20},8,[23],"The goal of this clinical trial is to evaluate changes in glucose and lipid levels after consuming challenge meals enriched with selected indigenous fruits and vegetables in people living with type 2 diabetes in Wakiso district.\n\nThe main question to answer is:\n\nDoes the consumption of challenge meals enriched with indigenous fruits and vegetables improve glucose and lipid levels among people living with type 2 diabetes? Researchers will compare the effects of different challenge meals on glucose and lipid levels to identify the indigenous fruit and vegetable with the strongest glucose- and lipid-lowering effects.\n\nParticipants will:\n\nConsume five challenge meals over 5 weeks. Visit the study site after a 5-7 day rest period to consume the challenge meal and complete the tests.",[117,118],"Type 2 Diabetes","Cardiometabolic Health",[120,121,122,123,124],"Type 2 diabetes","Challenge meals","Postprandial","Glucose metabolism","Indigenous fruits and Vegetables","2026-05-19",{"date":127,"type":36},"2026-05-22",{"date":129,"type":36},"2026-05-18",{"date":131,"type":20},"2026-08-30",{"name":42,"class":43},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":141,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":145,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},"100570640","a-prospective-multicenter-diagnostic-biomarker-study-to-discriminate-borderline-from-stage-i-invasive-ovarian-cancer-100570640","NCT06709872","A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer","Discriminating Borderline From Stage I Invasive Ovarian Cancer (BIOC): a Prospective Multicenter Diagnostic Biomarker Study","BIOC","Inclusion Criteria:\n\n* Participants eligible for inclusion in this study must meet all of the following criteria:\n\n  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n  2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n  3. Ultrasound discovery of a cyst on the ovary, suspicious for BOT or stage I invasive tumor (subjective assessment)\n\nExclusion Criteria:\n\n* Participants eligible for this Study must not meet any of the following criteria:\n\n  1. Participants younger than 18 years old,\n  2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive\n  3. Participants who refuse the preoperative transvaginal ultrasonography and\u002For blood sample\n  4. Participants with known simultaneous and\u002For previous malignancies within five years prior to BIOC participation\n  5. Participants with infectious serology (i.e. HIV, Hepatitis B, Hepatitis C)\n  6. Participants who deny or withdraw the written informed consent","FEMALE",{"count":143,"type":20},400,"1 Day","OBSERVATIONAL","The study aims to improve the diagnosis of ovarian cancer by distinguishing between borderline ovarian tumors (BOT) and stage I invasive ovarian cancer. Other than the traditional diagnostic biomarker CA125, the previous study TRANS-IOTA (translational-international ovarian tumor analysis; S51375\u002FS59207), conducted by similar investigators, pointed at biomarkers like HE4, CA72.4, CA15.3, and CCL11, as potential markers to discriminate BOT from stage I cancer. BIOC is the follow-up study, which will include four additional promising biomarkers to expand the panel to nine. The investigators aim to confirm whether a subpanel of these nine biomarkers has diagnostic value. Such a biomarker signature would enhance the accuracy of distinguishing between BOT and stage I invasive ovarian cancer before surgery, leading to more precise treatment and improved patient outcomes.",[148,149],"Stage I Ovarian Cancer","Borderline Ovarian Tumors",[151,152,153,154],"Borderline ovarian tumors","stage I ovarian cancer","diagnostic","biomarkers",{"date":127,"type":36},{"date":157,"type":36},"2025-06-03",{"date":159,"type":20},"2029-09-03",{"name":42,"class":43},4,{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":174,"briefSummary":175,"conditions":176,"keywords":179,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":73},"100635062","effects-of-a-robot-based-sensorimotor-upper-limb-rehabilitation-paradigm-in-chronic-stroke-100635062","NCT07547800","Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke","Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke: a Randomized Controlled Trial","RCT ROBUST","Inclusion Criteria stroke participants:\n\n1. Written informed consent must be obtained prior to any screening procedures;\n2. A first-ever unilateral, supra-tentorial stroke, as defined by WHO (rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular origin);\n3. ≥18 and ≤85 years old;\n4. Being a Dutch speaker;\n5. Being in the chronic phase after stroke, i.e. \\> 6 months post stroke;\n6. Motor impairment in the upper limb, defined as Fugl-Meyer score \\>22 out of 66 to demonstrate moderate to full upper limb motor function (patients scoring \\\u003C23 out of 66 will not be able to comply with the Kinarm protocol);\n7. Residual sensory upper limb impairment, defined as Tactile Discrimination Test (Area Under Curve) \\\u003C73.10%;\n8. Impaired functionality, defined as sensorimotor Action Research Arm Test score \\\u003C52 out of 57;\n9. Manageable spasticity for Kinarm tasks.\n\nInclusion Criteria healthy participants:\n\n1. Written informed consent must be obtained prior to any screening procedures;\n2. ≥18 and ≤85 years old;\n3. Being a Dutch or English speaker;\n4. No history of stroke or transient ischemic attack;\n5. No recent brain\u002Fhead injury;\n6. No major upper limb sensory or motor impairments.\n\nExclusion Criteria:\n\n1. Having musculoskeletal and\u002For other neurological disorders impacting care or prognosis;\n2. Having severe communication or cognitive deficits that interfere with the protocol;\n3. Having severe spasticity (cannot handle Kinarm robot);\n4. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP;\n5. Contraindications for robot-based therapy (e.g., uncontrolled epilepsy);\n6. Participation in another clinical investigation;\n7. Having any contraindications for fNIRS\\*：\n\n   * Uncontrolled head movements (e.g. tremor)\n   * Scalp lesion at optode sites (wound\u002Fincision\u002Finfection\u002Fhematoma)\n   * Decompressive craniectomy or large skull defect over target regions\n   * Persistent hair-optode coupling failure despite best practices, or non-removable obstructions preventing adequate coupling\n8. Having any contraindications for MRI\\*\\*:\n\n   * Pacemaker\n   * Implantable Cardioverter Defibrillator (ICD)\n   * Cochlear implant\n   * Internal Insulin-pump\n   * Deep brain stimulation\n   * Any other metal device in the body\n   * Claustrophobia\n   * Having a history of a neuropsychiatric or neurologic disorder before the diagnosis of stroke (e.g., depression, traumatic brain injury)\n   * Use of psychoactive medication before the diagnosis of stroke (e.g., anti-depressive medication)\n   * Misuse (or history of misuse) of drugs\u002Falcohol\n9. Currently undergoing a structured arm and\u002For hand training (e.g. engaging in playing a musical instrument)\\*\\*.\n\n   * Stroke patients and healthy participants showing these exclusion criteria will be included in the RCT protocol, but will not be measured with fNIRS.\n\n     * Stroke patients showing these exclusion criteria will be included in the RCT protocol, but will not be measured with MRI. Healthy adults showing these exclusion criteria will not be included in the study.",true,"85 Years",{"count":173,"type":20},109,[23],"Sensorimotor function of the upper limb is commonly impaired after stroke, even in the chronic phase (\\>6 months post-stroke). Nevertheless, good sensorimotor function is needed for daily life functioning. Sensorimotor function can be divided into three components: exteroception, proprioception and sensory processing. It is important that those three components will each be addressed in the upper limb rehabilitation. Unfortunately, there is still no optimal therapy to address sensory processing. Therefore, the investigators developed an intensive sensorimotor robot-based rehabilitation paradigm (called ROBUST) with focus on sensory processing. As a first step, the investigators did a pilot study (S69003) including 10 persons with chronic stroke to investigate the potential effectiveness and feasibility of this novel rehabilitation. The median change score of motor, sensory and sensorimotor assessments was exceeding the minimal clinical important difference (MCID), and the total amount of therapy was feasible as well. The investigated protocols to measure potential changes in brain function (activity and connectivity) and structure accompanying the novel therapy appeared feasible as well. Based on this first pilot study, the investigators finalized the protocol for this RCT to investigate the effectiveness of the ROBUST intervention.",[177,178],"Stroke","Healthy Adult",[177,180,181,182,183,184,185,186,187],"Upper limb","Sensorimotor","Sensory processing","Robot-based therapy","MRI","fNIRS","Clinical outcomes","Kinematic outcomes","2026-05-06",{"date":190,"type":36},"2026-05-11",{"date":192,"type":20},"2026-04-17",{"date":194,"type":20},"2027-12-31",{"name":42,"class":43},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},"100637518","aid-fog-artificial-intelligence-driven-freezing-of-gait-detection-in-the-home-100637518","NCT07580612","AID-FOG: Artificial Intelligence-Driven Freezing of Gait Detection in the Home","Artificial Intelligence-Driven Freezing Of Gait Detection in the Home: Investigating How Free-living Activities Affect the Algorithm","AID-FOG","Inclusion Criteria:\n\nFor all participants\n\n* Voluntary written informed consent of the participant has been obtained prior to any study-related procedures, except the non-recorded pre-screening questions;\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF);\n* Person is cognitively able to follow and understand instructions and provide voluntary written informed consent;\n* Person is able to walk for short distances (± 10 meters) independently, with- or without use of a walking aid;\n* Person does not live in a temporary or permanent care facility.\n\nFor participants with PD:\n\n* Clinical diagnosis of Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;\n* Person self-reports to experience daily FOG (for recruitment of freezers only);\n* Person is willing to temporarily delay the morning anti-Parkinsonian medication during the standardized assessment visit.\n\nExclusion criteria:\n\n* Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \\>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait;\n* Participant self-reports daily falls;\n* Participation in another interventional study, with or without an investigational medicinal product (IMP) or device (IMD)",{"count":205,"type":20},126,"Freezing of gait (FOG) is a debilitating symptom of Parkinson's disease increases the risk of falling. Despite being a common symptom, it is still difficult to evaluate freezing of gait quickly and accurately. Currently, the gold-standard method to determine the severity of FOG is a manual analysis of video footage by an experienced assessor, collected during standardized FOG-provoking walking tests. Because this is a very time-intensive process, where different assessors sometimes obtain different results, our team at KU Leuven have developed an artificial-intelligent (AI) algorithm trained to identify FOG episodes based on wearable inertial measurement unit (IMU) sensor data. The AI algorithm has already undergone initial validation during laboratory testing, yielding promising results. The aim of this study is to investigate whether the AI algorithm can accurately detect FOG episodes in a less controlled environment, namely the home environment. In a second phase, the investigators will also use the collected data to improve the AI algorithm for automated FOG detection in the home. Finally, the investigators want to explore whether the AI algorithm can detect FOG in real-time.",[208,209,210,211,212],"Parkinson Disease, Idiopathic","Freezing of Gait","Validation","Wearable Sensors","Artifical Intelligence","2026-05-05",{"date":215,"type":36},"2026-05-12",{"date":217,"type":36},"2025-09-22",{"date":219,"type":20},"2027-06",{"name":42,"class":43},3,{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":21,"phases":231,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":73},"100636806","phase-2-the-effect-of-cbd-on-sleep-quality-following-late-evening-exercise-100636806","NCT07570472","The Effect of CBD on Sleep Quality Following Late Evening Exercise","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Use of highly effective methods of birth control during the entire trial and for up to 4 months after the last dose of CBD; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.\n3. Age between 18-40 years old at the time of signing the Informed Consent Form (ICF)\n4. Recreationally active (between 2-8h\u002Fwk)\n5. Good health status confirmed by a sport medical screening\n6. Body fat percentage below 20% (males) or 25% (females) as estimated by a Dual-energy X-ray absorptiometry (DXA) scan\n7. Good sleep efficiency determined by the Pittsburgh Sleep Quality Index (PSQI, score ≤ 4)\n\nExclusion Criteria:\n\n1. Self-reported sleep disturbances\n2. Habitual smoking (\\> 1 occasion\u002Fmonth)\n3. Any kind of injury\u002Fincapability that is a contra-indication to perform high intensity interval training\n4. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n5. Participation in another interventional Trial with an investigational medicinal product (IMP) or device\n6. Use of CBD related products 3 months prior to the start of the experimental trial (including CBD oil, cannabis or other substances containing cannabinoids)\n7. Intake of any medication or nutritional supplement that influences sleep quality 3 months prior to the start of the experimental trial\n8. Shift workers or extreme morning and evening chronotypes (scores between 16-30 or 70-86 on the Morningness-Eveningness Questionnaire (MEQ))","40 Years",{"count":230,"type":20},20,[232],"PHASE2","The trial is a double-blind, placebo-controlled crossover design. In a randomized order, 20 participants undergo one control and two experimental sessions separated by a 1-week wash out period. During the no exercise\u002Frest session, participants' sleep is monitored via polysomnography following a rest day. During the training sessions participants' sleep is monitored following a high intensity interval training (HIIT) in the late evening (finishing 1h prior to bedtime). During these sessions participants receive 2x 200mg CBD or placebo in a randomized order.",[235],"Sleep Quality",[237,238,239,240],"Cannabidiol","Sleep quality","Late evening exercise","Polysomnography","2026-04-30",{"date":188,"type":36},{"date":244,"type":36},"2026-03-19",{"date":246,"type":20},"2026-06-07",{"name":42,"class":43},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":4,"eligibilityCriteria":254,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":271},"100634030","automated-cpet-interpretation-international-validation-study-100634030","NCT07534384","Automated CPET Interpretation: International Validation Study","International Validation Study of Automated Interpretation for Cardiopulmonary Exercise Testing","Patients referred for a cardiopulmonary exercise test (CPET):\n\nInclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* At least 18 years of age at the time of signing the Informed Consent Form\n* Patients referred for a CPET during their standard clinical care\n\nExclusion Criteria:\n\n\\- If the participant has a disorder making it unable to perform a CPET, they must not proceed to be enrolled in the study and will be documented as a screen failure via applicable log forms in the Investigator Site File.",{"count":256,"type":20},600,"The goal of this observational experimental study is to validate a rule-based algorithm to automate CPET interpretation.\n\nThe endpoints of this study are the following:\n\n* The change in agreement between key opinion leaders (KOLs) and the algorithm-generated CPET interpretation reports, comparing baseline to the end of the 6 month study period.\n* Baseline agreement between KOLs and the algorithm\n* Agreement at 6 months between KOLs and the algorithm\n* Change in self-reported confidence scores before and after using the automated report\n* Feedback on automated protocols generated via the platform during the 6-month implementation period\n* Descriptive evaluation of center-level CPET interpretation reports practices at three timepoints\n\nPatients referred for a CPET will be included to collect observational data without interference within clinical routine. KOLs will be recruited from participating centres to fill out a survey for CPET interpretations.",[259],"Cardiopulmonary Exercise Test",[261,262],"CPET","automated interpretation","2026-04-15",{"date":265,"type":36},"2026-04-16",{"date":267,"type":20},"2026-03-30",{"date":269,"type":20},"2026-11-30",{"name":42,"class":43},2,{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":73},"100537158","personalized-care-pathways-for-bowel-symptoms-in-rectal-cancer-patientsdevelopment-of-e-diary-100537158","NCT06274190","Personalized Care Pathways for Bowel Symptoms in Rectal Cancer patients_development of E-diary","Towards Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients Through Precision Medicine","Treatable","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n* Proficient in reading, comprehending, and conversing in Dutch .\n* Patients after rectal surgery for rectal cancer or under Watch and Wait protocol (also referred to as active surveillance).\n\nExclusion Criteria:\n\n* The participant has undergone a different type of surgery, including a Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection.\n* Experienced fecal incontinence prior to undergoing surgery.\n* Are affected by neurological disorders affecting bowel function.\n* Already underwent previous pelvic radiation or rectal surgery for non-cancer reasons.",{"count":281,"type":20},158,[23],"Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection, combined with chemoradiotherapy. However, this treatment will negatively impact different aspects of bowel function and the patients' quality of life. These bowel symptoms often remain prevalent, even at 12 months after RC treatment. Most assessment tools are however not capable of capturing the full range or therapeutic-related evolution of these bowel symptoms. Consequently, the aim is to develop a validated bowel diary for diagnosing and evaluation of all bowel symptoms.\n\nIn recent years, organ-preserving strategies such as Watch and Wait have become more widely implemented. Although these patients avoid surgical morbidity, emerging evidence shows that neoadjuvant radiotherapy alone can also cause substantial and persistent bowel dysfunction. Therefore, the study population was expanded to include patients managed with a Watch and Wait strategy in addition to those undergoing TME\u002FPME.",[285,286],"Rectal Cancer","LARS - Low Anterior Resection Syndrome",[288,289,290],"Bowel diary","Quality of Life (QoL)","Care pathway","2026-04-13",{"date":263,"type":36},{"date":294,"type":36},"2024-04-29",{"date":296,"type":20},"2026-07",{"name":42,"class":43},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":73},"100632054","cerebellar-research-in-ultrasound-stimulation-100632054","NCT07508696","Cerebellar Research in Ultrasound Stimulation","CERBERUS","Inclusion Criteria:\n\n* Experiment 1: Healthy Volunteers\n\n  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n  2. Participants aged 18-55 years\n  3. Male of female\n  4. Good health with no history of serious mental illness or implanted metal\n  5. Willingness to adhere to the TUS and MRI study schedule\n  6. Willingness to avoid caffeine and alcohol intake for at least 2 h prior to the investigation\n* Experiment 2: ET Patients\n\n  1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n  2. Participants aged 18-75 years\n  3. Male of female\n  4. Diagnosis of ET as confirmed from clinical history and examination by a movement disorder neurologist\n  5. Willingness to adhere to the TUS and MRI study schedule\n  6. Willingness to avoid caffeine and alcohol intake for at least 2 h prior to the investigation\n\nExclusion Criteria:\n\n* Experiment 1: Healthy volunteers\n\n  1. Currently taking any psychotropic medication\n  2. Any head trauma resulting in loss of consciousness\n  3. Diagnosed with a serious mental illness\n  4. Alcohol or substance abuse or dependence (other than tobacco) in the past week\n  5. Currently in treatment for a psychiatric condition\n  6. Pregnancy (a test will be scheduled by the research team)\n  7. Personal or family history of seizures or epilepsy\n  8. Claustrophobia or inability to stay still in the MR scanner environment\n  9. Any metal in the body that is not MRI-compatible\n  10. Serious history of migraines\n  11. Hair in dreadlocks, braids, or weave (not possible to position ultrasound transducer)\n  12. orthopedic forearm or hand problems\n  13. Inability to adhere to the experimental schedule.\n* Experiment 2: ET Patients\n\n  1. Currently taking any psychotropic medication\n  2. Implanted with a non-MRI compatible medical device\n  3. History of thalamotomy\n  4. Skin lesions at stimulation site\n  5. Peripheral neuropathy\n  6. neurologic exam not consistent with ET\n  7. Any head trauma resulting in loss of consciousness\n  8. Diagnosed with a serious mental illness\n  9. Alcohol or substance abuse or dependence (other than tobacco) in the past week\n  10. alcohol or caffeine consumption within 12 hours of study enrollment.\n  11. Currently in treatment for a psychiatric condition\n  12. Pregnancy (scheduled test)\n  13. Personal or family history of seizures or epilepsy\n  14. Claustrophobia or inability to stay still in the MR scanner environment\n  15. Any metal in the body that is not MRI-compatible\n  16. Serious history of migraines\n  17. Hair in dreadlocks, braids, or weave\n  18. orthopedic forearm or hand problems\n  19. Inability to adhere to the experimental schedule.","75 Years",{"count":53,"type":20},[23],"Experiment 1: Modulation of Physiological Tremor in Healthy Volunteers Thirty healthy volunteers will undergo TUS targeting the dentate nucleus in a randomized, double-blinded crossover design. Tremor amplitude, induced by a 15 g weight, will be measured using an accelerometer, and EEG will assess neural oscillations and cerebello-thalamo-cortical connectivity.\n\nStimulation will include short-term (1 minute on\u002Foff for 12 minutes) and long-term (30 minutes) protocols, as well as closed-loop TUS for phase-specific effects. This experiment aims to optimize stimulation parameters and explore the dentate nucleus's role in tremor generation.\n\nExperiment 2: Tremor Modulation in Essential Tremor Patients Thirty ET patients will receive TUS targeting the dentate nucleus with optimized parameters from Experiment 1 in a randomized crossover design. The best protocol from previous experiment will be tested here. Tremor amplitude and EEG will be recorded to assess short- and long-term effects of TUS on pathological tremor.",[310],"Essential Tremor",[312,313,310,314,315,316,317,318],"transcranial focused ultrasound stimulation","TUS","ET","Movement disorders","Neuromodulation","NIBS","non-invasive brain stimulation","2026-03-31",{"date":321,"type":36},"2026-04-02",{"date":323,"type":20},"2026-06-01",{"date":325,"type":20},"2028-10-01",{"name":42,"class":43},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":161},"100625201","belgian-lung-function-study-100625201","NCT07419555","Belgian Lung Function Study","Belgian Lung Function Study: Personalised Longitudinal Lung Function Analysis as a Marker of Disease Progression","AIRCAST","Inclusion Criteria:\n\n* Above 18 years old\n* Diagnosed with a chronic respiratory disease and followed up in one of the participating Belgian hospitals\n* Performed a complete lung function test (spirometry, body plethysmography and diffusion capacity) at baseline\n* Have at least 3 historical spirometry measurements over a minimal time window of 2 years prior to inclusion\n* Planned routine follow-up within standard clinical care in one of the participating hospitals\n\nExclusion Criteria:\n\n* Patients who have had a lung transplantation\n* Patients not being able to give consent to participate",{"count":336,"type":20},4000,"Currently, it remains unclear how to manage serial lung function measurements in a clinical setting. The investigators aimed to tackle this problem by developing a machine learning (ML) model that can accurately predict population and individual lung function trajectories. These predictions would enable the investigators to identify positive or negative deviations, thereby revealing unexpected disease patterns.\n\nA prospective validation is needed that includes data on mortality, hospitalisations, emergency-room visits and patient-reported outcomes. Within this study, the goal is to validate the ML model with the data collected from this observational study.",[339],"Chronic Respiratory Diseases",[341,342,343],"lung function","trajectory","predictions","2026-03-25",{"date":267,"type":36},{"date":344,"type":36},{"date":348,"type":20},"2029-03-01",{"name":42,"class":43},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":356,"eligibilityCriteria":357,"healthyVolunteers":170,"sex":141,"minAge":18,"maxAge":228,"enrollmentInfo":358,"targetDuration":4,"studyType":21,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":73},"100416066","effect-of-hyaluronan-enriched-medium-on-the-cumulative-ongoing-pregnancy-rate-100416066","NCT04697823","Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate.","Effect of Hyaluronan-enriched Medium on the Cumulative Ongoing Pregnancy Rate: a Prospective Randomized Trial","TETHER","Inclusion Criteria:\n\n* Patients with own oocytes\u002Fembryos;\n* Patients with female age at 1st OR in the study \\\u003C40 year;\n* Patients planned for a 2nd oocyte retrieval, with no clinical ongoing pregnancy after the previous oocyte retrieval\n* Patients planned for a 3rd oocyte retrieval with no clinical ongoing pregnancy after previous oocyte retrievals\n* Patients with female age at 1st OR in the study \\\u003C40 year;\n* Patients with BMI ≤32;\n* Patients with written informed consent;\n\nExclusion Criteria:\n\n\\-",{"count":143,"type":20},[23],"Assessing whether the use of hyaluronan-enriched transfer medium can increase the cumulative ongoing pregnancy rate",[362,363],"Hyaluronan-EnRiched Medium","Randomized Controlled Trial",{"date":267,"type":36},{"date":366,"type":36},"2021-01-01",{"date":368,"type":20},"2026-12-31",{"name":42,"class":43},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":380,"conditions":381,"keywords":384,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":73},"100202481","measuring-nerve-activity-in-small-human-intestinal-biopsies-in-ibs-irritable-bowel-syndrome-100202481","NCT01912313","Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)","Inclusion Criteria:\n\n* IBS patients (based on ROME III Criteria)\n* Healthy subjects\n\nExclusion Criteria:\n\n\\- All subjects with not IBS related complaints","99 Years",{"count":378,"type":20},99999999,[23],"Rectal biopsies from IBS patients or healthy subjects will be taken.\n\nBiopsies will be used for:\n\n1. the isolation of submucosal plexus to perform: 1.1 live nerve recordings and Calcium imaging; 1.2 immunohistochemistry; 1.3 mRNA (Messenger ribonucleic acids) isolation and real time PCR (Polymerase chain reaction);\n2. culturing biopsies\n\nOn the basis of these observations, the general aim of the study is to move a significant step forward in the current knowledge on human ENS (enteric nervous system) in IBS by establishing a live imaging method to record enteric nerves activity in small intestinal biopsies from humans. This development is unique in its kind as not other research groups have reported successful live recordings with calcium imaging in this preparation.\n\nIn particular, the investigators aim:\n\n1. to develop and validate the technique to measure activity in human enteric nerves in the submucous plexus isolated from rectal biopsies from healthy subjects and IBS patients;\n2. to characterize this nerve activity in healthy subjects and IBS patients using both calcium imaging to evaluate the effect of different neuromodulators, immunohistochemistry and rtPCR to determine receptor expression levels and identify neurons and glial cells in the submucous ganglia;\n3. to investigate whether the biopsies of IBS patients secrete more modulators\u002Fcytokines compared to healthy subjects and their potential to activate neurons.\n4. to evaluate the influence of different food constituents (cow\"s milk, wheat, yeast, gluten and soy) on the local reaction of the rectal mucosa and evaluate mast cell activation\u002Fdegranulation in biopsies of IBS patients compared to healthy subjects.\n5. To evaluate the amount of inflammatory mediators\u002Fmetabolites in urine samples of IBS patients and healthy volunteers by the use of metabolic profiling",[382,383],"IBS","Healthy",[385,386],"IBS patients","healthy subjects",{"date":388,"type":36},"2026-03-20",{"date":390,"type":4},"2013-08",{"date":392,"type":20},"2026-12",{"name":42,"class":43},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":404,"conditions":405,"keywords":406,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":271},"100555835","aha-boost-arm-hand-boost-therapy-to-enhance-recovery-after-stroke-clinical-health-economic-and-process-evaluation-100555835","NCT06517251","Aha BOOST Arm-hand BOOST Therapy to Enhance Recovery After Stroke: Clinical, Health Economic and Process Evaluation","AHA-BOOST","Inclusion Criteria:\n\n* Maximally 5 months after a first-ever unilateral, supra-tentorial stroke\n* Minimally 18 years old\n* A residual inpatient stay of minimally 4 weeks\n* The ability to sit independently\n* Motor impairment in the upper limb, as defined, based on the JSU diagram, as a score of 8-17 on stage 2 (synergies) of the Fugl-Meyer assessment upper extremity (FMA-UE) or a score of \\\u003C8 on stage 2 of the FMA-UE, combined with a score of \\>6 on stage 5 (hand) of the FMA-UE.\n\nExclusion Criteria:\n\n* Severe communication deficits as defined as a score of \\\u003C24 out of 32 on the 'visual sentence comprehension' subscale of the Comprehensive Aphasia Test.\n* Severe cognitive deficits as defined as a score of \\\u003C18 out of 30 on the Montreal Cognitive Assessment.",{"count":402,"type":20},80,[23],"The overall aim of this study is to establish the clinical- and cost-effectiveness of the arm-hand BOOST therapy when delivered on top of the usual care program in the sub-acute phase post stroke and to perform a process evaluation.\n\nIn this phase III RCT, 80 patients with stroke will be recruited from two inpatient stroke rehabilitation wards in Belgium and randomized to the experimental group receiving arm-hand BOOST therapy or the control group receiving the L-BOOST intervention, on top of their usual inpatient care program. The arm-hand BOOST program (1 hour\u002Fday, 5x\u002Fweek, 4 weeks) consists of group exercises based on four key aspects, namely neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. Additionally, technology-supported upper limb therapy will be provided two times 30 minutes per week. The L-BOOST intervention comprises a dose-matched program of lower limb exercises and general reconditioning. At baseline, after 4 weeks of training, 3 months after the intervention and at 12 months post stroke, outcome assessment will be performed. The primary outcome measure is the action research arm test (ARAT). Secondary outcomes include measures in the domain of upper limb function and capacity, independence, participation and quality of life. Multivariate ANOVA and sensitivity analyses will be used to compare change from baseline between groups. Information on medical costs will be collected to allow a health economic evaluation. Finally, a process evaluation will be performed to assist in identifying why arm-hand BOOST succeeds or fails unexpectedly or has unanticipated consequences, and how this can be optimized.\n\nAt the start of this study the investigators hypothesize that: (I) Aha BOOST will result in a significant greater improvement in arm-hand activity post-intervention, at follow-up and 12 months post stroke compared to control therapy (L-BOOST); (II) Aha BOOST will result in a significant greater improvement in upper limb function, performance, independence and activity of daily living, and participation post-intervention, at follow up and 12 months post stroke. (III) Investing in 24 hours of extra arm-hand therapy to subacute stroke patient in the inpatient rehabilitation setting can reduce the health-economic and societal cost 12 months post stroke.",[177],[407,408,409,410,411,412,413,414],"Randomized controlled trial","Upper extremity","Subacute stroke","Inpatient rehabilitation","Additional therapy","Clinical evaluation","Health-economic evaluation","Process evaluation","2026-03-18",{"date":244,"type":36},{"date":418,"type":36},"2024-06-17",{"date":420,"type":20},"2027-12",{"name":42,"class":43},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":141,"minAge":18,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":21,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":73},"100629595","peer-modeled-intervention-100629595","NCT07476716","Peer-modeled Intervention","The Effect of a Peer-modeled Complex Behavioural Change Intervention on the Cardio-metabolic Health of Women in Mbarara City, Uganda","Inclusion Criteria:\n\n* Women of reproductive age (WRA; 18 to 49 years).\n* With central obesity measured as a waist circumference of \\> 80cm and up to 88 cm.\n* They should consent and be willing to follow a 3-month active intervention and a 3-month post-intervention follow-up.\n* They should be residents of Mbarara City.\n* They should either speak English or Runyakitara\u002FRunyankore.\n\nExclusion Criteria:\n\n* Pregnant and lactating for six months.\n* Taking anti-diabetic or hypertension medication.\n* Physically incapacitated to stand for measurements or speak","49 Years",{"count":431,"type":20},157,[23],"The goal of this clinical trial is to learn about the effects of a peer-led behavioural change intervention on the cardio-metabolic health of women aged 18 to 49 years. The main question it aims to answer is:\n\n-Does a peer-led behavioural change intervention improve the cardio-metabolic health of women aged 18 to 49 years?\n\nResearchers will compare food literacy, physical literacy, and awareness with a comparison arm that receives only information on doable actions to improve cardio-metabolic health in a small booklet.\n\nThe participants will:\n\n* Participants in the intervention arm will have group activities on food literacy, physical literacy and awareness for 3 months of the active phase of the intervention.\n* The participants in the intervention arm will be followed up with a phone call in between the active phase of the intervention.\n* At the beginning of the study, the participants in the comparison arm will receive a small booklet with inforgraphics on ways to improve their cardio-metabolic health, with no further contact.\n* All the participants will not be contacted in any form for the next 3 months after the active phase of the intervention.\n* The participants will be measured for their waist circumference, fat mass, blood pressure, lipid and glucose levels, and arterial stiffness.\n* The participants will also be assessed for physical activity levels, dietary intake, body size preferences, self-efficacy, social support, self-monitoring, and self-esteem.",[435],"Cardio-metabolic Health",[437,438,439,440,441,442,443],"Peer-modeled","behavioural","women","behavioural change","Uganda","cardio-metabolic","central adiposity","2026-03-17",{"date":244,"type":36},{"date":447,"type":20},"2026-05-01",{"date":449,"type":20},"2026-12-20",{"name":42,"class":43},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":459,"targetDuration":4,"studyType":21,"phases":461,"briefSummary":462,"conditions":463,"keywords":465,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":73},"100581093","point-of-care-troponin-testing-in-the-emergency-department-100581093","NCT06845826","Point-of-Care Troponin Testing in the Emergency Department","Point-of-Care High-Sensitivity Troponin Testing in the Emergency Department to Assess Myocardial Infarction for Timely Discharge","CERMIT","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures - At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Age \\\u003C 75 years of age\n* Presenting with chest pain or chest pain-equivalent symptom suspect of acute coronary syndrome at the University Hospitals Leuven emergency department; Symptoms must have (had) a minimum duration of 15 minutes, and the current, ongoing episode of symptoms must have started within the past 12 hours.\n\nExclusion Criteria:\n\n* Unable to provide written informed consent\n* Age \\\u003C18 years or \\>75 years\n* Chest pain or equivalent symptom with a duration shorter than 15 minutes, or an onset of the current, ongoing episode of symptoms more than 12 hours ago\n* Clinically unstable patients or confirmed STEMI patients, requiring immediate treatment\n* Patients with recent chest trauma\n* Patients transferred from another hospital\n* Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CISP.",{"count":460,"type":20},1552,[23],"The goal of this study is to evaluate whether a POC-guided testing strategy to exclude non-ST elevation myocardial infarction (NSTEMI) in acute chest pain patients presenting at the emergency department (ED) can result in a shorter length of stay compared to the routine central laboratory testing strategy. Currently, most often two high-sensitivity troponin (hs-cTn) tests are required for exclusion of NSTEMI, and central laboratories are struggling to achieve the recommended turnaround time of 60 minutes. Novel POC hs-cTn testing technology can provide results in minutes, potentially reducing the ED length of stay. This may lead to a reduction in ED crowding, which is a growing worldwide healthcare problem, resulting in poorer patient outcomes. This study may therefore improve patient burden, ED staff workload, and lead to more efficient expenditure of healthcare resources.\n\nWe will perform a prospective, cross-sectional, interventional, single-center, open label, randomized trial.\n\nAll consecutive patients older than 18 years and younger than 75 years presenting at the UZ Leuven emergency department with chest pain or chest pain-equivalent symptoms suspected of an acute coronary syndrome (ACS) will be invited to participate in the study. After informed consent patients will be randomized into the point-of-care testing (POCT) group or the usual care group. Patients in the POCT group will undergo the novel POC test-guided strategy. In the POC strategy the first hs-cTnI test shortly after admission to the ED will be performed on the POC Atellica VTLi. The second test will be performed with the usual central laboratory hs-cTnT test. Patients in the usual care group will undergo the usual testing strategy with one or two hs-cTnT tests performed in the hospital's central laboratory.",[464],"Acute Coronary Syndromes",[466,467,468],"POCT","troponine testing","acute coronary syndrome","2026-03-16",{"date":415,"type":36},{"date":472,"type":36},"2025-06-30",{"date":474,"type":20},"2026-12-30",{"name":42,"class":43},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":21,"phases":485,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":73},"100460739","locomotor-muscle-oxygenation-and-activation-during-acute-interval-compared-to-constant-load-bed-cycling-exercise-100460739","NCT05279547","Locomotor Muscle Oxygenation and Activation During Acute Interval Compared to Constant-load Bed-cycling Exercise","Locomotor Muscle Oxygenation and Activation During Acute Interval Compared to Constant-load Bed-cycling Exercise: A Pilot Study","Inclusion Criteria:\n\n* Full cooperatively adult patients indicated by the Adequacy Score of standardized 5 questions (SQ5) = 5\u002F5\n* Patients mechanically ventilated for longer than 48 hours during the same ICU admission\n* Patients are expected to remain in the ICU for more than an additional 48 hours starting from study enrollment\n* Patients able to perform active cycling for \\> 10 consecutive minutes\n\nExclusion Criteria:\n\n* Pre-existing functional limitations\n* Low limb injuries or conditions that would preclude in-bed cycling such as a body habitus unable to fit the bike\n* Extreme obesity (body mass index \\>35 kg\u002Fm2)\n* Neurologically unstable\n* Acute surgery\n* Palliative goals of care\n* Temperature \\> 40 °C\n* An anticipated fatal outcome\n* Evidence of coronary ischaemia, for example, chest pain or electrocardiogram changes\n* Resting heart rate \\\u003C40 or \\>120 beats per minute\n* Mean arterial pressure \\\u003C60 or \\>120 mmHg\n* Peripheral capillary oxygen saturation \\\u003C 90%\n* Wounds, trauma or surgery of leg precluding cycle ergometry\n* Wounds, trauma or surgery of pelvis precluding cycle ergometry\n* Wounds, trauma or surgery of lumbar spine precluding cycle ergometry\n* Coagulation disorder (international normalised ratio \\> 1.8, or platelets \\\u003C 50,000 mcL)\n* Intracranial pressure \\>20 mm Hg\n* Femoral access other than femoral central line\n* Acute deep vein thrombosis\n* Pulmonary embolism\n* \\>20 mcg\u002Fmin of noradrenaline\n* inotropic or vasopressor support comparable to a dose of noradrenaline \\>20mcg\u002Fmin\n* Fraction of inspired oxygen \\> 55%\n* Arterial partial pressure of oxygen (PaO2) \\\u003C65 torr (\\\u003C8.66 kPa)\n* Positive end-expiratory pressure \\> 10 cmH2O\n* Respiratory rate \\> 30 breaths per minutes with adequate ventilatory support\n* Minute ventilation \\>150 mL\u002Fkg body weight",{"count":484,"type":20},100,[23],"Up to 60% of patients admitted to the Intensive Care Unit (ICU) with a prolonged stay in the ICU develop complications such as intensive care unit acquired weakness (ICUAW) characterized by limb and respiratory muscle weakness. ICUAW is associated with worse prognosis, longer ICU stay and increased morbidity and mortality.\n\nPhysical therapy (PT) interventions in the intensive care unit (ICU), can improve patients' outcomes.\n\nHowever, improvements in muscle function achieved with standard physical activity interventions aiming at early mobilization are highly variable due to lack of consistency in definition of the interventions, lack of consideration for the complexity of exercise dose and\u002For insufficient stimulation of muscles during interventions. It has been suggested that modifying early mobilization and exercise protocols towards shorter intervals consisting of higher intensity exercises might result in more optimal stimulation of muscles.\n\nIn the present study the researchers therefore aim to simultaneously assess (by non-invasive technologies) locomotor muscle oxygenation and activation along with the measurements of the load imposed on respiration and circulation during two different training modalities i.e., moderate intensity continuous bed-cycling (endurance training) vs high-intensity alternated by lower intensity periods of bed-cycling (interval training).",[488,489],"Intensive Care Unit Acquired Weakness","Critical Illness",[491,492,493,494,495,496,497,498,499],"ICU acquired muscle weakness","Quadriceps muscle","Near-infrared spectroscopy","Oxygenation","EMG","Early-mobilization","Bed-cycling","Interval exercise","Continuous exercise",{"date":415,"type":36},{"date":502,"type":36},"2023-02-01",{"date":504,"type":20},"2028-12",{"name":42,"class":43},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":21,"phases":515,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":531,"leadSponsor":533,"locationsCount":73},"100413048","improving-our-understanding-of-respiratory-muscle-training-to-facilitate-weaning-from-mechanical-ventilation-in-the-icu-100413048","NCT04658498","Improving Our Understanding of Respiratory Muscle Training to Facilitate Weaning From Mechanical Ventilation in the ICU","TrainToWean","Inclusion Criteria:\n\n* Difficult and prolonged weaning patients\n* Adequate oxygenation\n* Febrile temperature \\\u003C 38ºC\n* Hemodynamic stability\n* Stable blood pressure\n* No or minimal vasopressors\n* No myocardial ischemia\n* Adequate hemoglobin and mentation\n* Resolution of disease acute phase\n* Able to follow simple verbal commands related to IMT\n* Mechanically ventilated via a tracheostomy or endotracheal tube\n\nExclusion Criteria:\n\n* Pre-existing neuromuscular disease\n* Agitation\n* Hemodynamically instable (arrhythmia, decompensated heart failure, coronary insufficiency)\n* Hemoptysis\n* Diaphoresis\n* Spinal cord injury above T8\n* Use of any type of home MV support prior to hospitalization\n* Skeletal pathology that impairs chest wall movements\n* Poor general prognosis or fatal outcome",{"count":514,"type":20},90,[23],"Mechanical ventilation is a life-saving treatment frequently applied in intensive care unit (ICU). Nonetheless, by putting at rest the respiratory muscles, it can lead to respiratory muscle weakness and atrophy, which are accompanied by prolonged duration of mechanical ventilation, difficult weaning and increased ICU mortality. Despite a strong theoretical rationale and some evidence supporting the use of inspiratory muscle training (IMT) to address respiratory muscle weakness and atrophy, the optimal approach to IMT remains largely uncertain. In fact, mechanistic studies evaluating physiological adaptations that occur in respiratory muscles of mechanically ventilated patients in response to different training regimens have not been conducted so far.\n\nThe aim of this study is to comprehensively investigate changes in respiratory muscle function in response to three different conditions that patients will be exposed to during their period of weaning from mechanical ventilation.",[518],"Weaning Failure",[491,520,521,522,523,524,525,526,527,528],"IMT","Weaning outcomes","Maximal inspiratory pressure","Diaphragm EMG","Surface EMG","Diaphragm ultrasounds","Microbiopsies","Difficult to wean patients","Respiratory muscles",{"date":415,"type":36},{"date":502,"type":36},{"date":532,"type":20},"2026-10",{"name":42,"class":43},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":21,"phases":544,"briefSummary":545,"conditions":546,"keywords":548,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":73},"100619622","prescription-support-system-for-antimicrobial-use-in-belgian-primary-care-100619622","NCT07347015","Prescription Support System for Antimicrobial Use in Belgian Primary Care","Impact Evaluation of a Prescription Search Support (PSS) for Antimicrobials Using a Stepped-Wedge Cluster Randomized Design in Belgian Primary Care","PaSSo","Inclusion Criteria:\n\n* General practices in Belgium using compatible EHR systems.\n* Willingness to use and activate the PSS by giving consent.\n* Agreement to participate in the study, provided signed informed consent form is in place.\n\nExclusion Criteria:\n\n* Practices using an EHR system that solely allows a single sign-on to the standalone PSS.\n* Practices already using a similar PSS or participating in overlapping projects.",{"count":543,"type":20},48,[23],"Inappropriate antibiotic prescribing in primary care remains an important contributor to antimicrobial resistance. Despite the availability of evidence-based clinical guidelines, antibiotics are still frequently prescribed for self-limiting infections. Digital clinical decision support tools may help general practitioners (GPs) align prescribing decisions with guideline recommendations during patient consultations.\n\nThis study evaluates the impact of a digital Prescription Support System (PSS) designed to support antimicrobial prescribing in Belgian primary care. The PSS provides guideline-based recommendations derived from the Belgian BAPCOC guidelines for common infections in ambulatory care. Recommendations are presented through a user-friendly decision tree that is integrated into existing electronic health record systems and can be consulted during routine care.\n\nThe study is embedded within the national implementation strategy of the PSS coordinated by the National Institute for Health and Disability Insurance (RIZIV-INAMI). A stepped-wedge cluster randomized design is used, in which participating general practices transition sequentially from usual care to access to the PSS over four predefined implementation steps. This approach ensures that all participating practices eventually receive access to the system while allowing comparisons over time.\n\nThe primary objective is to assess whether implementation of the PSS is associated with changes in antibiotic prescribing in Belgian general practice. Prescribing outcomes are measured using routinely collected indicators from the Belgian Antibiotic Barometer, including overall antibiotic prescribing rates and the use of broad- versus narrow-spectrum antibiotics. Secondary objectives include assessing the usability and acceptability of the PSS among clinicians and identifying factors that influence its adoption in daily practice. The study will also monitor potential unintended consequences, such as changes in workflow or concerns about underprescribing.\n\nFindings from this study will inform future decisions regarding further optimization and wider implementation of the PSS in Belgian primary care.",[547],"Infectious Diseases",[549,550,551,552,553],"Antimicrobial Stewardship","Primary Care","Clinical Decision Support","Stepped-Wedge Cluster Randomized Trial","Antibiotics","2026-03-05",{"date":556,"type":36},"2026-03-06",{"date":558,"type":36},"2025-12-21",{"date":560,"type":20},"2027-03-31",{"name":42,"class":43},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":569,"targetDuration":4,"studyType":21,"phases":571,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":73},"100542685","molecular-analysis-for-gastro-esophageal-cancer-multicenter-discrete-choice-experiment-100542685","NCT06346080","Molecular Analysis for Gastro-Esophageal Cancer: Multicenter Discrete Choice Experiment","MAGECmultiDiCE","Inclusion Criteria:\n\n1. Individuals \\>18yo to 75yo (upper age limit of Barrett's surveillance)\n2. Access to computer or smartphone\n3. Clear understanding of available languages of the experiment (English, French, Dutch, Spanish, German, Chinese, Japanese)\n\nExclusion Criteria:\n\n1. Individuals less than 18yo and more than 75yo\n2. Incarcerated individuals",{"count":570,"type":20},2200,[23],"The goal of this survey is to investigate the participants' preference for a specific screening\u002Fdiagnostic tool to detect and assess gastro-esophageal cancer.\n\nThe main question it aims to answer are:\n\n* Which diagnostic modality is preferred by patients and the general population?\n* Which features of the diagnostic test are most detrimental in the decision-making for one or the other modality?\n* Are geographical differences present in regard to the preference for a diagnostic modality?\n\nParticipants will be asked to complete a survey of 20-25min, including a brief intake regarding their socio-economic status. This approach will allow us to correct for confounding factors.",[574,575],"Esophageal Cancer","Gastric Cancer",[577,578,579],"Esophageal cancer","Survey","Gastric cancer","2026-02-14",{"date":582,"type":36},"2026-02-18",{"date":584,"type":36},"2024-08-01",{"date":586,"type":20},"2026-08-01",{"name":42,"class":43},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":595,"enrollmentInfo":596,"targetDuration":4,"studyType":21,"phases":598,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":610,"leadSponsor":612,"locationsCount":73},"100542683","molecular-assessment-for-gastro-esophageal-cancer-100542683","NCT06346054","Molecular Assessment for Gastro-Esophageal Cancer","MAGEC","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any breath or blood analysis\n2. \\>18 years old\n3. Barrett's esophagus or treatment naïve gastro-esophageal cancer stage I to IV\n4. Voluntary healthy controls\n\nExclusion Criteria:\n\n1. \\\u003C18 years old\n2. Patient has history of:\n\n   1. Active other cancer than gastro-esophageal cancer\n   2. Prior cancer treated \\\u003C3 years ago\n   3. Hepatic dysfunction\u002Fliver failure (MELT \\>7)\n3. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the study plan.\n4. Insufficient\u002Funreliable quality of breath (e.g., breath flow) or plasma sample (e.g., haemolytic sample)\n5. Incarcerated individuals","100 Years",{"count":597,"type":20},1000,[23],"The goal of this minimally invasive interventional study is to learn if oncometabolic biomarkers, detected in the exhaled breath and blood can identify early-stage gastro-oesophageal cancer in patient at risk for gastro-oesophageal cancer.\n\nThe main questions this study aims to answer:\n\nAre oncometabolites proficient and reproducible enough to function as diagnostic biomarkers? Can these biomarkers identify early-stage gastro-esophageal cancer? Researchers will compare participants with gastro-oesophageal cancer to healthy controls and participants with Barrett's esophagus to detect meaningful differences between the groups.\n\nParticipants will provide a breath and blood sample during their routine standard of care visits.",[574,575,601],"Barrett Esophagus",[603,604,605,606],"Oncometabolites","Early-stage cancer","Diagnostic testing","Screening",{"date":608,"type":36},"2026-02-17",{"date":584,"type":36},{"date":611,"type":20},"2029-07-01",{"name":42,"class":43},{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":621,"targetDuration":4,"studyType":21,"phases":622,"briefSummary":623,"conditions":624,"keywords":628,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":73},"100624744","the-acute-effect-of-exercise-type-and-timing-on-ambulatory-blood-pressure-and-intra-ocular-pressure-in-individuals-with-glaucoma-the-achieve-project-100624744","NCT07413614","The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma (The ACHIEVE-project).","The ACHIEVE-project: Advancing Cardiovascular and Ocular Health In Eye Patients. The Acute Effect of Exercise Type And Timing on Ambulatory Blood Pressure and Intra-Ocular Pressure in Individuals With Glaucoma.","ACHIEVE","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Patients with POAG AND \\[elevated BP OR hypertension (Average SBP on office BP and Home BP ≥120 mmHg AND\u002FOR Average DBP on office BP and Home BP ≥70 mmHg 26) with or without the use of anti-hypertensive medication\\]\n* Patients without recent changes in medication and glaucoma care within the past four weeks.\n\nExclusion Criteria:\n\n* Not able to provide informed consent\n* SBP and\u002For DBP are ≥ 150 mmHg and\u002For ≥ 95 mmHg, respectively, on office BP at screening AND on home BP measurement conducted in the week following screening (to identify White Coat Hypertension) to ensure safety. These patients require referral for early treatment.\n* Aberrant cardiopulmonary exercise test (CPET) at screening (Life-threatening arrhythmias, ischemia,…)\n* Unable to perform one or more of the four exercise sessions due to physical and or mental limitations (severe lung disease, musculoskeletal issues, unstable angina,…)\n* Severe osteoarthritis pending knee replacement surgery (these patients may be unable to perform the IRE (i.e. wall squat exercise)\n* Unable to communicate in Dutch\n* Active malignancy\n* Participation in an interventional Trial with an investigational medicinal product (IMP), exercise intervention or device\n* Unwillingness to repeat ABPM\n* Relative contraindications to ABPM: diagnosed atrial fibrillation, nighttime workers, occupational drivers",{"count":53,"type":20},[23],"ACHIEVE aims to determine whether exercise can be a safe and effective non-drug approach to improve blood pressure control in patients with primary open-angle glaucoma (POAG). Although exercise is a promising and potentially well-accepted therapy, its use in clinical care is limited because the safety and effectiveness of different exercise types (aerobic, isometric, moderate, or high intensity) and timing (morning versus evening) have not been systematically studied in people with POAG and elevated blood pressure.\n\nThis study will evaluate the safety and short-term effects of different exercise modalities and timings on 24-hour ambulatory blood pressure and blood pressure variability in patients with POAG and elevated blood pressure.\n\nIt is hypothesized that:\n\n* Each exercise session will lead to a temporary reduction in blood pressure (post-exercise hypotension).\n* The greatest and longest-lasting reduction will occur after high-intensity aerobic exercise performed in the morning.\n\nIt is also expected that all exercise types and timings will be safe for participants.",[625,626,627],"Glaucoma Open-Angle Primary","Hypertension","Elevated Blood Pressure",[629,630,631,632,633,634,626,635,636],"Ambulatory blood pressure","High intensity interval training","Isometric Exercise","Intra-ocular pressure","Moderate continuous training","Primary open angle glaucoma","Blood pressure variability","Exercise","2026-02-09",{"date":608,"type":36},{"date":640,"type":20},"2026-04",{"date":642,"type":20},"2027-03",{"name":42,"class":43},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":277,"acronym":278,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":21,"phases":652,"briefSummary":653,"conditions":654,"keywords":656,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":663,"locationsCount":73},"100586351","personalized-care-pathways-for-bowel-symptoms-in-rectal-cancer-patientscontributing-factors-treatable-100586351","NCT06914245","Personalized Care Pathways for Bowel Symptoms in Rectal Cancer Patients_contributing Factors (Treatable)","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF).\n* Proficient in reading, comprehending, and conversing in Dutch.\n* Patients scheduled for Total Mesorectal Excision (TME) or Partial Mesorectal Excision (PME) or 'Watch and wait' protocol due to rectal cancer.\n\nExclusion Criteria:\n\n* The participant has undergone a different type of surgery, including a Hartmann procedure, abdominoperineal excision, transanal endoscopic microsurgery, or sigmoid resection.\n* Experienced fecal incontinence prior to undergoing surgery.\n* Are affected by neurological disorders affecting bowel function.\n* Already underwent previous pelvic radiation or rectal surgery for non-cancer reasons.\n* Has a permanent stoma.",{"count":651,"type":20},150,[23],"Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection combined with chemoradiotherapy. However, this treatment negatively affects various aspects of bowel function and patients' quality of life. These bowel symptoms often remain prevalent, even 12 months after RC treatment.\n\nThe aim of this study is to identify the factors contributing to persistent bowel symptoms and their long-term impact on quality of life following treatment for rectal cancer, assessed 12 months after surgery or stoma closure in surgically treated patients, and 12 months after completion of neoadjuvant therapy in patients managed with active surveillance\u002Fwatch-and-wait. These insights are crucial for developing an effective care approach, as they help determine when specific evaluations should be conducted and which treatments should be applied at different stages.",[285,286,655],"Active Surveillance",[288,289,290],"2026-01-22",{"date":659,"type":36},"2026-01-23",{"date":661,"type":36},"2025-04-28",{"date":504,"type":20},{"name":42,"class":43},{"id":665,"slug":666,"hasResults":12,"nctId":667,"briefTitle":668,"officialTitle":669,"acronym":670,"eligibilityCriteria":671,"healthyVolunteers":170,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":672,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":674,"conditions":675,"keywords":679,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":73},"100621214","the-influence-of-chemotherapy-on-position-sense-100621214","NCT07367711","The Influence of Chemotherapy on Position Sense","Multifaced Approach of Assessing Upper Extremity Proprioception in Breast Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy","ProprioCIPN","Inclusion Criteria\n\nGeneral (applies to all participants):\n\n* At least 18 years of age at the time of signing the informed consent form\n* Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n\nBreast cancer surgery-only patient group:\n\n* The patient is an adult oncological person between 18 and 75 years old who has been treated for cancer\n* The participant has undergone breast cancer surgery but has not received any radiotherapy or chemotherapy treatment (yet).\n* The first session takes place between two and six weeks after breast cancer surgery.\n* The second session takes before any follow-up treatment for breast cancer (radiotherapy or chemotherapy).\n\nChemotherapy group:\n\n* The patient is an adult oncological person between 18 and 75 years old who has been treated for cancer.\n* The participant has undergone breast cancer surgery but has not received any radiotherapy (yet).\n* Participant has a history of treatment with platinum- or taxane-based chemotherapeutic agents, and this treatment has been terminated no later than 6 weeks before the first session.\n\nHealthy control group:\n\n* No history of cancer or chemotherapy treatment\n* Sex and age-matched to patient sample\n\nExclusion Criteria:\n\nGeneral (applies to all participants):\n\n* Participant has a history of mental or physical disorders or neurological disease beyond those related to cancer treatments.\n* Participant uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study.\n* Participant is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks which, in the investigator's opinion, might confound the results of the study.\n* Participant suffered from peripheral neuropathy prior to the chemotherapeutic treatment (Only for patients).\n* Participant has (a history of) a lesion in the central nervous system that is known to possibly cause neuropathic pain: e.g. spinal cord injury, infarction localized in the brainstem or thalamus, syringomyelia, multiple sclerosis, or any other disorder of the CNS that, in the investigator's opinion, may cause neuropathic pain.\n* If applicable: Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive",{"count":673,"type":20},145,"Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent side-effects of chemotherapy, causing sensory and motor symptoms in patients. CIPN development is especially prevalent in chemotherapy treatment involving platinum- and taxane-based agents. The accompanying pain and deficits greatly impact the quality of life of these patients. Currently, patients are assessed for altered somatosensory using quantitative sensory testing (QST). The German Research Network on Neuropathic Pain (DFNS) has developed a standardized protocol which has been internationally recognized as approach for performing the QST. However, for proprioception the QST is limited to vibration assessments, making it limited as the only test to measure proprioception. Therefore, a comprehensive assessment of the proprioceptive functions is needed to better understand the influence CIPN has on the proprioception of patients, and thereby their quality of life.\n\nIn this project the effects of chemotherapy on somatosensory and proprioceptive functioning of breast cancer patients will be assessed in a cross-sectional study. This will be tested by comparing two groups of breast cancer patients and a healthy control group. Both patient groups will have undergone surgery for breast cancer, however, only one group will be tested after undergoing additional chemotherapy treatment. Thereby, the effects of chemotherapy between the surgery-only patient group and the chemotherapy patient group can tested. Furthermore, the investigators will compare both patient groups to sex- and age-matched healthy controls.",[676,677,678],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","Chemotherapy-Induced Peripheral Neuropathy","Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer",[680,681,682,683,677,684,685,686,687,688,689],"Proprioception","Position Sense","CIPN","Breast Cancer","Motor Control","Motion Capture","Marker-less","QST","Quantitative Sensory Testing","Robotic Assessment","2026-01-19",{"date":692,"type":36},"2026-01-26",{"date":694,"type":20},"2026-02",{"date":696,"type":20},"2027-11",{"name":42,"class":43},""]